KSI-028: Tetrahydroquinoline-Based STING Inhibitor Bioactivity Data

KSI-028 represents a newly discovered tetrahydroquinoline-based chemotype for inhibiting the STING protein, which is implicated in inflammatory diseases. The dataset, published by So Hyeon Jeong in 2026, includes results from mechanistic studies and in vivo efficacy testing in a cisplatin-induced acute kidney injury mouse model. It demonstrates the compound's ability to suppress STING-dependent signaling and reduce cytokine production in murine and human cells.

Use Cases

• Training predictive models for STING inhibitor activity based on the tetrahydroquinoline scaffold.
• Benchmarking new compounds against the noncanonical binding mode described for KSI-028.
• Analyzing structure-activity relationships for STING inhibitors with alternative target engagement.
• Validating in silico screening results for anti-inflammatory drug candidates using the reported in vivo efficacy data.

Strengths

• Dataset is small (2.8 KB), enabling quick download and initial inspection.
• Data is associated with a specific, novel chemotype (tetrahydroquinoline) and compound (KSI-028) described in a detailed scientific abstract.
• Includes evidence of in vivo efficacy against acute kidney injury in a mouse model.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 2.8 KB file size suggests a very limited scope, likely containing summary or key result data rather than extensive raw measurements.

Provenance

Source

figshare, authored by So Hyeon Jeong.

Collection Method

Likely contains experimental results from the discovery and characterization of the KSI-028 compound.

Freshness

Last updated 2026-04-18 13:34:12; freshness should be verified.